Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy.
about
Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapyMalignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysisPeritoneal carcinomatosis of colorectal origin.A phase I trial of thermal sensitization using induced oxidative stress in the context of HIPEC.Tailoring heated intraperitoneal mitomycin C for peritoneal metastases originating from colorectal carcinoma: a translational approach to improve survival.Splenectomy revisited in 2011: Impact on hematologic toxicities while performing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Methodology, Drugs and Bidirectional ChemotherapySafe temperature range for intraoperative and early postoperative continuous hyperthermic intraperitoneal perfusion in a swine model of experimental distal gastrectomy with Billroth II reconstructionIntraperitoneal chemotherapy from Armstrong to HIPEC: challenges and promise.Recommendations and consensus on the treatment of peritoneal metastases of colorectal origin: a systematic review of national and international guidelines.Utility of Chemoresponse Assay in Patients Undergoing Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy.The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study.Neoadjuvant chemotherapy followed by fast-track cytoreductive surgery plus short-course hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced ovarian cancer: preliminary results of a promising all-in-one approach.A Multi-Center Randomized Trial to Evaluate Hematologic Toxicities after Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin or Mitomycin in Patients with Appendiceal Tumors.Current Management of Peritoneal Carcinomatosis From Colorectal Cancer: The Role of Cytoreductive Surgery and Hyperthermic Peritoneal Chemoperfusion.A proposal of Brazilian Society of Surgical Oncology for standardizing cytoreductive surgery plus hypertermic intraperitoneal chemotherapy procedures in Brazil: pseudomixoma peritonei, appendiceal tumors and malignant peritoneal mesothelioma.Core Body Temperature but Not Intraabdominal Pressure Predicts Postoperative Complications Following Closed-System Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Administration.The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study.Implications of Hyperthermic Intraperitoneal Chemotherapy Perfusion-Related Hyperglycemia.Population pharmacokinetics of hyperthermic intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis after cytoreductive surgery.Applications of hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer.Standard Clinical Protocol for Bidirectional Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Systemic Leucovorin, 5-Fluorouracil, and Heated Intraperitoneal Oxaliplatin in a Chloride-Containing Carrier Solution.Optimization of drug delivery systems for intraperitoneal therapy to extend the residence time of the chemotherapeutic agent.
P2860
Q26768402-60EB2563-B8C6-4F16-AB0F-2F366A4118EFQ33909330-542BA673-1A18-4262-90C9-3F91041038F4Q34391090-58F91873-F782-4DB6-A892-1BA17B1A6C19Q34564775-84D1F7DE-AE39-4305-87D5-CB3FFABB21B8Q35678699-BBB4CF76-B698-4565-BABC-157CDC1E90B5Q36097165-5B59BD8F-2E6B-4F05-9D0F-D026C6C12B43Q36758933-F00B2FCA-9E6C-47C5-876F-3E4722ECDF20Q37071401-53C7825F-9306-474C-B9AC-41B2C0EED34DQ38171356-87C35135-5489-46FE-BB93-EA0329B71A67Q38778938-8A7C6933-C596-4F97-A067-F1BFEBFCEF4DQ41603309-B32E42AB-F0A2-4715-9470-C4B8D266FF51Q44667185-EC8C8021-7364-481D-BE6C-B8B351856576Q47151877-E6241C38-A1D2-4791-A7E3-984177D2F5BFQ47553847-83A862AA-629E-4DC5-B18C-E2A8CEB019D3Q47569322-AF94A904-078A-42EC-9C57-4A070F2DDF70Q47821560-95A2BFA9-6B03-41DE-8F7E-BC9BA24B78F0Q48334242-B6513F31-9486-4320-8B21-10249CFF41DCQ48901514-8C78C9BA-F02B-4166-ACF2-13EF935F0F19Q50076428-04F3EAF4-8735-41BB-B214-79B1D035D8C3Q50111382-40F231B3-8650-44DA-BCE3-C8F4732A6206Q51825453-2988290B-DC4D-4843-B495-5559E8D274BBQ52952846-B211AF0B-87BA-485B-9D29-27930819F3CEQ55135995-6CB9212B-6509-4604-B3D6-E40E2B9823EA
P2860
Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy.
@en
Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy.
@nl
type
label
Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy.
@en
Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy.
@nl
prefLabel
Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy.
@en
Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy.
@nl
P50
P356
P1476
Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy
@en
P2093
Elias Dominique
Rami Younan
P2860
P304
P356
10.1002/JSO.21051
P577
2008-09-01T00:00:00Z